Status:
COMPLETED
A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This randomized study will assess the effect of adding bevacizumab to trastuzumab plus docetaxel in neoadjuvant therapy in participants with early stage human epidermal growth factor receptor 2 (HER2)...
Eligibility Criteria
Inclusion
- Participants with early stage HER2-positive breast cancer
- Scheduled to receive neoadjuvant therapy with the objective of conservative surgery
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Exclusion
- Participants with partial or total lobular carcinoma
- Participants with inflammatory breast cancer
- Previous treatment with chemotherapy, radiation therapy or hormonal therapy for breast cancer
- Previous history of cancer (other than curatively treated basal and squamous cell carcinoma of the skin and/or in situ carcinoma of the cervix) relapsing within the 5 years before study entry or in situ contralateral breast carcinoma
Key Trial Info
Start Date :
May 19 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2017
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT01142778
Start Date
May 19 2010
End Date
December 13 2017
Last Update
March 16 2018
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Radiotherapie Marie Curie
Arras, France, 62000
2
Centre Hospitalier; Hematologie-Oncologie
Beauvais, France, 60021
3
Clinique Tivoli; Sce Radiotherapie
Bordeaux, France, 33000
4
Hopital Augustin Morvan; Federation De Cancerologie
Brest, France, 29200